Cyclacel gets Nasdaq extension to Dec 24, 2024 to meet equity minimum

Bio Green Med Solution, Inc.

Nasdaq Hearing Panel granted until Dec 24, 2024 to regain compliance with Rule 5550(b)(1).
Company had stockholders' equity below $2.5 million as of June 30, 2024.
No assurance compliance will be met; delisting risk remains if not regained by deadline.
Listing Council may review panel decision within 45 days of Oct 22, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.